Subtherapeutic oral anticoagulant therapy: Frequency and risk factors
Summary Subtherapeutic anticoagulation levels increase both the risk and severity of thromboembolism. The aim of this study was to determine the cumulative incidence of subtherapeutic international normalised ratios (INRs) and to identify risk factors associated with a low INR. We performed a cohort...
Gespeichert in:
Veröffentlicht in: | Thrombosis and haemostasis 2009-03, Vol.101 (3), p.552-556 |
---|---|
Hauptverfasser: | , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 556 |
---|---|
container_issue | 3 |
container_start_page | 552 |
container_title | Thrombosis and haemostasis |
container_volume | 101 |
creator | Rombouts, Eva K. Rosendaal, Frits R. van der Meer, Felix J. M. |
description | Summary
Subtherapeutic anticoagulation levels increase both the risk and severity of thromboembolism. The aim of this study was to determine the cumulative incidence of subtherapeutic international normalised ratios (INRs) and to identify risk factors associated with a low INR. We performed a cohort study in 7,419 patients from a Dutch anticoagulation clinic. Patients who started a first treatment with oral anticoagulants between January 2000 and December 2005 and who were stably anticoagulated (4 consecutive INRs in the therapeutic range) were included. Within the cohort a nested case control study was performed to identify risk factors of subtherapeutic INRs and to determine how often a subtherapeutic INR is the result of medical interference in case of invasive procedures, hospital admissions, haemorrhage or overanticoagulation. In patients with a stable anticoagulation, the median time to a first low INR was 40 weeks. A subtherapeutic INR occurred twice as often in patients using acenocoumarol as in those using phenprocoumon (hazard ratio [HR] 2.1, 95% confidence interval [95%CI]:2.0 – 2.3) and was more common in patients with a high therapeutic range compared to a low therapeutic range (HR 1.8, 95%CI:1.5 – 2.2). Occurrence of a low INR also depended on indication for anticoagulant therapy, with the highest risk in patients who used anticoagulants as prophylaxis and the lowest risk in patients with mechanical heart valves. In 30% of cases the subtherapeutic INR was preceded by an event necessitating vitamin K or discontinuation of the anticoagulant drug. |
doi_str_mv | 10.1160/TH08-09-0626 |
format | Article |
fullrecord | <record><control><sourceid>pubmed_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1160_TH08_09_0626</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>19277419</sourcerecordid><originalsourceid>FETCH-LOGICAL-c650t-fb8c725e74bb558e604fd3e57e72fd40494b1bd6363e5fdbe4587c6aab414e6e3</originalsourceid><addsrcrecordid>eNq9kE2L1TAUhoMoznV051q6caXVpDcfjTsZZhxhwIUjuAtJempzbZuaD-X-e1N6GQVxJ65ycs7DeTgvQk8JfkUIx69vr3FbY1lj3vB7aNcwLmreys_30Q7vKa55Q9kZehTjAWPCqWQP0RmRjRCUyB26_JhNGiDoBXJytvJBj5WeS-n1lzyWqtrGxzfVVYBvGWZ7LEBXBRe_Vr22yYf4GD3o9Rjhyek9R5-uLm8vruubD-_eX7y9qS1nONW9aa1oGAhqDGMtcEz7bg9MgGj6jmIqqSGm43temn1ngLJWWK61oYQCh_05ernttcHHGKBXS3CTDkdFsFrTUGsaCku1plHwZxu-ZDNB9ws-nV-A5ydAR6vHPujZunjHNYS0kjFWuBcblwYHE6iDz2Euh_5N2210tINOSWcIdyvTEPxkfCyWEqIaNEw-Jr3-rZ8TzKkMgh3cd1AuxgwqLmCdHtWk5xxtcEsqVilXzeEfagQRfyhUHPwPNaRpLLL5P9z0m_AncFXz2Q</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Subtherapeutic oral anticoagulant therapy: Frequency and risk factors</title><source>MEDLINE</source><source>Thieme Connect Journals</source><creator>Rombouts, Eva K. ; Rosendaal, Frits R. ; van der Meer, Felix J. M.</creator><creatorcontrib>Rombouts, Eva K. ; Rosendaal, Frits R. ; van der Meer, Felix J. M.</creatorcontrib><description>Summary
Subtherapeutic anticoagulation levels increase both the risk and severity of thromboembolism. The aim of this study was to determine the cumulative incidence of subtherapeutic international normalised ratios (INRs) and to identify risk factors associated with a low INR. We performed a cohort study in 7,419 patients from a Dutch anticoagulation clinic. Patients who started a first treatment with oral anticoagulants between January 2000 and December 2005 and who were stably anticoagulated (4 consecutive INRs in the therapeutic range) were included. Within the cohort a nested case control study was performed to identify risk factors of subtherapeutic INRs and to determine how often a subtherapeutic INR is the result of medical interference in case of invasive procedures, hospital admissions, haemorrhage or overanticoagulation. In patients with a stable anticoagulation, the median time to a first low INR was 40 weeks. A subtherapeutic INR occurred twice as often in patients using acenocoumarol as in those using phenprocoumon (hazard ratio [HR] 2.1, 95% confidence interval [95%CI]:2.0 – 2.3) and was more common in patients with a high therapeutic range compared to a low therapeutic range (HR 1.8, 95%CI:1.5 – 2.2). Occurrence of a low INR also depended on indication for anticoagulant therapy, with the highest risk in patients who used anticoagulants as prophylaxis and the lowest risk in patients with mechanical heart valves. In 30% of cases the subtherapeutic INR was preceded by an event necessitating vitamin K or discontinuation of the anticoagulant drug.</description><identifier>ISSN: 0340-6245</identifier><identifier>EISSN: 2567-689X</identifier><identifier>DOI: 10.1160/TH08-09-0626</identifier><identifier>PMID: 19277419</identifier><identifier>CODEN: THHADQ</identifier><language>eng</language><publisher>Stuttgart: Schattauer Verlag für Medizin und Naturwissenschaften</publisher><subject>Acenocoumarol - administration & dosage ; Acenocoumarol - adverse effects ; Acenocoumarol - therapeutic use ; Adult ; Aged ; Aged, 80 and over ; anticoagulant stability ; Anticoagulants - administration & dosage ; Anticoagulants - adverse effects ; Anticoagulants - therapeutic use ; Biological and medical sciences ; Blood coagulation. Blood cells ; Cohort Studies ; Female ; Fundamental and applied biological sciences. Psychology ; Hematologic and hematopoietic diseases ; Hemorrhage - etiology ; Humans ; INR ; International Normalized Ratio ; Male ; Medical sciences ; Middle Aged ; Molecular and cellular biology ; New Technologies, Diagnostic Tools and Drugs ; oral anticoagulants ; Phenprocoumon - administration & dosage ; Phenprocoumon - adverse effects ; Phenprocoumon - therapeutic use ; Platelet diseases and coagulopathies ; Risk Factors ; Thromboembolism - etiology ; Thromboembolism - prevention & control ; Time Factors</subject><ispartof>Thrombosis and haemostasis, 2009-03, Vol.101 (3), p.552-556</ispartof><rights>2009 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c650t-fb8c725e74bb558e604fd3e57e72fd40494b1bd6363e5fdbe4587c6aab414e6e3</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.thieme-connect.de/products/ejournals/pdf/10.1160/TH08-09-0626.pdf$$EPDF$$P50$$Gthieme$$H</linktopdf><linktohtml>$$Uhttps://www.thieme-connect.de/products/ejournals/html/10.1160/TH08-09-0626$$EHTML$$P50$$Gthieme$$H</linktohtml><link.rule.ids>314,776,780,3005,27901,27902,54534,54535</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=21189555$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/19277419$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Rombouts, Eva K.</creatorcontrib><creatorcontrib>Rosendaal, Frits R.</creatorcontrib><creatorcontrib>van der Meer, Felix J. M.</creatorcontrib><title>Subtherapeutic oral anticoagulant therapy: Frequency and risk factors</title><title>Thrombosis and haemostasis</title><addtitle>Thromb Haemost</addtitle><description>Summary
Subtherapeutic anticoagulation levels increase both the risk and severity of thromboembolism. The aim of this study was to determine the cumulative incidence of subtherapeutic international normalised ratios (INRs) and to identify risk factors associated with a low INR. We performed a cohort study in 7,419 patients from a Dutch anticoagulation clinic. Patients who started a first treatment with oral anticoagulants between January 2000 and December 2005 and who were stably anticoagulated (4 consecutive INRs in the therapeutic range) were included. Within the cohort a nested case control study was performed to identify risk factors of subtherapeutic INRs and to determine how often a subtherapeutic INR is the result of medical interference in case of invasive procedures, hospital admissions, haemorrhage or overanticoagulation. In patients with a stable anticoagulation, the median time to a first low INR was 40 weeks. A subtherapeutic INR occurred twice as often in patients using acenocoumarol as in those using phenprocoumon (hazard ratio [HR] 2.1, 95% confidence interval [95%CI]:2.0 – 2.3) and was more common in patients with a high therapeutic range compared to a low therapeutic range (HR 1.8, 95%CI:1.5 – 2.2). Occurrence of a low INR also depended on indication for anticoagulant therapy, with the highest risk in patients who used anticoagulants as prophylaxis and the lowest risk in patients with mechanical heart valves. In 30% of cases the subtherapeutic INR was preceded by an event necessitating vitamin K or discontinuation of the anticoagulant drug.</description><subject>Acenocoumarol - administration & dosage</subject><subject>Acenocoumarol - adverse effects</subject><subject>Acenocoumarol - therapeutic use</subject><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>anticoagulant stability</subject><subject>Anticoagulants - administration & dosage</subject><subject>Anticoagulants - adverse effects</subject><subject>Anticoagulants - therapeutic use</subject><subject>Biological and medical sciences</subject><subject>Blood coagulation. Blood cells</subject><subject>Cohort Studies</subject><subject>Female</subject><subject>Fundamental and applied biological sciences. Psychology</subject><subject>Hematologic and hematopoietic diseases</subject><subject>Hemorrhage - etiology</subject><subject>Humans</subject><subject>INR</subject><subject>International Normalized Ratio</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Molecular and cellular biology</subject><subject>New Technologies, Diagnostic Tools and Drugs</subject><subject>oral anticoagulants</subject><subject>Phenprocoumon - administration & dosage</subject><subject>Phenprocoumon - adverse effects</subject><subject>Phenprocoumon - therapeutic use</subject><subject>Platelet diseases and coagulopathies</subject><subject>Risk Factors</subject><subject>Thromboembolism - etiology</subject><subject>Thromboembolism - prevention & control</subject><subject>Time Factors</subject><issn>0340-6245</issn><issn>2567-689X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2009</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNq9kE2L1TAUhoMoznV051q6caXVpDcfjTsZZhxhwIUjuAtJempzbZuaD-X-e1N6GQVxJ65ycs7DeTgvQk8JfkUIx69vr3FbY1lj3vB7aNcwLmreys_30Q7vKa55Q9kZehTjAWPCqWQP0RmRjRCUyB26_JhNGiDoBXJytvJBj5WeS-n1lzyWqtrGxzfVVYBvGWZ7LEBXBRe_Vr22yYf4GD3o9Rjhyek9R5-uLm8vruubD-_eX7y9qS1nONW9aa1oGAhqDGMtcEz7bg9MgGj6jmIqqSGm43temn1ngLJWWK61oYQCh_05ernttcHHGKBXS3CTDkdFsFrTUGsaCku1plHwZxu-ZDNB9ws-nV-A5ydAR6vHPujZunjHNYS0kjFWuBcblwYHE6iDz2Euh_5N2210tINOSWcIdyvTEPxkfCyWEqIaNEw-Jr3-rZ8TzKkMgh3cd1AuxgwqLmCdHtWk5xxtcEsqVilXzeEfagQRfyhUHPwPNaRpLLL5P9z0m_AncFXz2Q</recordid><startdate>20090301</startdate><enddate>20090301</enddate><creator>Rombouts, Eva K.</creator><creator>Rosendaal, Frits R.</creator><creator>van der Meer, Felix J. M.</creator><general>Schattauer Verlag für Medizin und Naturwissenschaften</general><general>Schattauer GmbH</general><general>Schattauer</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>20090301</creationdate><title>Subtherapeutic oral anticoagulant therapy: Frequency and risk factors</title><author>Rombouts, Eva K. ; Rosendaal, Frits R. ; van der Meer, Felix J. M.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c650t-fb8c725e74bb558e604fd3e57e72fd40494b1bd6363e5fdbe4587c6aab414e6e3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2009</creationdate><topic>Acenocoumarol - administration & dosage</topic><topic>Acenocoumarol - adverse effects</topic><topic>Acenocoumarol - therapeutic use</topic><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>anticoagulant stability</topic><topic>Anticoagulants - administration & dosage</topic><topic>Anticoagulants - adverse effects</topic><topic>Anticoagulants - therapeutic use</topic><topic>Biological and medical sciences</topic><topic>Blood coagulation. Blood cells</topic><topic>Cohort Studies</topic><topic>Female</topic><topic>Fundamental and applied biological sciences. Psychology</topic><topic>Hematologic and hematopoietic diseases</topic><topic>Hemorrhage - etiology</topic><topic>Humans</topic><topic>INR</topic><topic>International Normalized Ratio</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Molecular and cellular biology</topic><topic>New Technologies, Diagnostic Tools and Drugs</topic><topic>oral anticoagulants</topic><topic>Phenprocoumon - administration & dosage</topic><topic>Phenprocoumon - adverse effects</topic><topic>Phenprocoumon - therapeutic use</topic><topic>Platelet diseases and coagulopathies</topic><topic>Risk Factors</topic><topic>Thromboembolism - etiology</topic><topic>Thromboembolism - prevention & control</topic><topic>Time Factors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Rombouts, Eva K.</creatorcontrib><creatorcontrib>Rosendaal, Frits R.</creatorcontrib><creatorcontrib>van der Meer, Felix J. M.</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><jtitle>Thrombosis and haemostasis</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Rombouts, Eva K.</au><au>Rosendaal, Frits R.</au><au>van der Meer, Felix J. M.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Subtherapeutic oral anticoagulant therapy: Frequency and risk factors</atitle><jtitle>Thrombosis and haemostasis</jtitle><addtitle>Thromb Haemost</addtitle><date>2009-03-01</date><risdate>2009</risdate><volume>101</volume><issue>3</issue><spage>552</spage><epage>556</epage><pages>552-556</pages><issn>0340-6245</issn><eissn>2567-689X</eissn><coden>THHADQ</coden><abstract>Summary
Subtherapeutic anticoagulation levels increase both the risk and severity of thromboembolism. The aim of this study was to determine the cumulative incidence of subtherapeutic international normalised ratios (INRs) and to identify risk factors associated with a low INR. We performed a cohort study in 7,419 patients from a Dutch anticoagulation clinic. Patients who started a first treatment with oral anticoagulants between January 2000 and December 2005 and who were stably anticoagulated (4 consecutive INRs in the therapeutic range) were included. Within the cohort a nested case control study was performed to identify risk factors of subtherapeutic INRs and to determine how often a subtherapeutic INR is the result of medical interference in case of invasive procedures, hospital admissions, haemorrhage or overanticoagulation. In patients with a stable anticoagulation, the median time to a first low INR was 40 weeks. A subtherapeutic INR occurred twice as often in patients using acenocoumarol as in those using phenprocoumon (hazard ratio [HR] 2.1, 95% confidence interval [95%CI]:2.0 – 2.3) and was more common in patients with a high therapeutic range compared to a low therapeutic range (HR 1.8, 95%CI:1.5 – 2.2). Occurrence of a low INR also depended on indication for anticoagulant therapy, with the highest risk in patients who used anticoagulants as prophylaxis and the lowest risk in patients with mechanical heart valves. In 30% of cases the subtherapeutic INR was preceded by an event necessitating vitamin K or discontinuation of the anticoagulant drug.</abstract><cop>Stuttgart</cop><pub>Schattauer Verlag für Medizin und Naturwissenschaften</pub><pmid>19277419</pmid><doi>10.1160/TH08-09-0626</doi><tpages>5</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0340-6245 |
ispartof | Thrombosis and haemostasis, 2009-03, Vol.101 (3), p.552-556 |
issn | 0340-6245 2567-689X |
language | eng |
recordid | cdi_crossref_primary_10_1160_TH08_09_0626 |
source | MEDLINE; Thieme Connect Journals |
subjects | Acenocoumarol - administration & dosage Acenocoumarol - adverse effects Acenocoumarol - therapeutic use Adult Aged Aged, 80 and over anticoagulant stability Anticoagulants - administration & dosage Anticoagulants - adverse effects Anticoagulants - therapeutic use Biological and medical sciences Blood coagulation. Blood cells Cohort Studies Female Fundamental and applied biological sciences. Psychology Hematologic and hematopoietic diseases Hemorrhage - etiology Humans INR International Normalized Ratio Male Medical sciences Middle Aged Molecular and cellular biology New Technologies, Diagnostic Tools and Drugs oral anticoagulants Phenprocoumon - administration & dosage Phenprocoumon - adverse effects Phenprocoumon - therapeutic use Platelet diseases and coagulopathies Risk Factors Thromboembolism - etiology Thromboembolism - prevention & control Time Factors |
title | Subtherapeutic oral anticoagulant therapy: Frequency and risk factors |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-28T13%3A45%3A59IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Subtherapeutic%20oral%20anticoagulant%20therapy:%20Frequency%20and%20risk%20factors&rft.jtitle=Thrombosis%20and%20haemostasis&rft.au=Rombouts,%20Eva%20K.&rft.date=2009-03-01&rft.volume=101&rft.issue=3&rft.spage=552&rft.epage=556&rft.pages=552-556&rft.issn=0340-6245&rft.eissn=2567-689X&rft.coden=THHADQ&rft_id=info:doi/10.1160/TH08-09-0626&rft_dat=%3Cpubmed_cross%3E19277419%3C/pubmed_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/19277419&rfr_iscdi=true |